<p><strong>Intramuscular-</strong><br />
Acromegaly:</p>

<ul>
	<li><strong>Adult:</strong>&nbsp;Following initial control with SC therapy: As a depot preparation, initially 20 mg every 4 wk. Adjust if required after 3 mth to 10-30 mg every 4 wk. Max: 40 mg every 4 wk.</li>
</ul>

<p><strong>Intravenous-</strong><br />
Variceal haemorrhage in patients with cirrhosis:</p>

<ul>
	<li><strong>Adult:</strong>&nbsp;As continuous IV infusion: 25 mcg/hr for 48 hr (up to 5 days in patients at high risk of re-bleeding).</li>
	<li><strong>Child:</strong>&nbsp;&ge;1 mth: 1 mcg/kg/hr (up to 50 mcg/hr); given as continuous IV infusion. Higher doses may be needed initially, reduce dose gradually over 24 hr until bleeding has stopped.</li>
</ul>

<p><strong>Subcutaneous-</strong><br />
Prophylaxis of complications following pancreatic surgery:</p>

<ul>
	<li><strong>Adult:</strong>&nbsp;100 mcg tid of a rapid-acting preparation given for 7 consecutive days, starting at least 1 hr before operation.</li>
</ul>

<p><strong>Subcutaneous-</strong><br />
Acromegaly:</p>

<ul>
	<li><strong>Adult:</strong>&nbsp;Initially 50 mcg tid, increased as necessary to usual dose 100-200 mcg tid. Max: 500 mcg tid.</li>
</ul>

<p><strong>Subcutaneous-</strong><br />
Secretory neoplasms:</p>

<ul>
	<li><strong>Adult:</strong>&nbsp;Initially, 50 mcg 1-2 times daily, increased gradually to up to 600 mcg daily in 2-4 divided doses according to response. Continued treatment is not recommended if there is no benefit within a wk of starting treatment for carcinoid tumour. Initial dose may be given via IV admin of a rapid response is required.</li>
</ul>

<p><strong>Subcutaneous-</strong><br />
HIV-associated diarrhoea:</p>

<ul>
	<li><strong>Adult:</strong>&nbsp;Initial dose 100 mcg tid. If symptoms are not controlled after 1 wk, increase dose to 250 mcg tid, if still not effective after 1 wk stop therapy.</li>
</ul>